Papers
2
Total Citations
21
H-Index
2
About
Johannes Czernin is a pioneering figure in molecular imaging and theranostics, whose work has fundamentally reshaped the management of prostate cancer and other malignancies. As a leading nuclear medicine physician and researcher, his primary contributions lie in the development and clinical translation of prostate-specific membrane antigen (PSMA)-targeted PET imaging and radioguided therapy. His landmark prospective trial on PSMA radioguided salvage lymphadenectomy for recurrent prostate cancer, published in 2024, has established a new paradigm for treating oligometastatic disease, demonstrating the feasibility of precisely removing PSMA-avid lesions to delay systemic therapy. Beyond prostate cancer, Czernin has been instrumental in advancing novel tracers like 68Ga-FAPI-46 for fibroblast activation protein imaging, as shown in his 2020 work on incidental elastofibroma detection, which highlights the broad applicability of these agents across various cancers. With a career spanning decades and thousands of citations, his research has directly improved patient outcomes by enabling earlier, more accurate detection of disease and guiding targeted, personalized treatments. Czernin’s relentless pursuit of innovation continues to set the standard for precision oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2